Tirzepatide is a once-weekly injection

Wegovy (Novo Nordisk) Patient Support Program Eligibility: Must have private insurance that covers Wegovy, not receiving government drug benefits Savings: Up to $150 per monthly prescription for 12 months Maximum annual benefit: $1,800 How it works: Reduces out-of-pocket costs after insurance pays their portion Saxenda (Novo Nordisk) Patient Support Program Eligibility: Private insurance covering Saxenda, not on provincial drug plans Savings: Up to $120 per monthly prescription Maximum annual benefit: $1,440 How it works: Applied at pharmacy, reduces copay amount Expected Retatrutide Program (Not Yet Announced) Projected eligibility: Private insurance with Retatrutide coverage, not receiving provincial benefits Projected savings: $200-300 per monthly prescription based on medication cost Projected maximum benefit: $2,400-3,600 annually Expected launch: Same time as Health Canada approval The catch with Canadian savings programs: you need private insurance that already covers the medication

Unfortunately, after earthquakes, sometimes there's tsunamis
In March 2026, the FDA issued multiple warning letters to vendors, clarifying that if a substance is marketed for its biological effects in humans (like muscle repair or weight loss), it is legally a drugregardless of the research only label
Reynolds, K
For example, GLP-1s offer cardioprotective effects, likely mediated by improved endothelial function and reduced inflammation